Skip to main content

Table 1 Clinical and pharmacological characteristics of the patients.

From: Decreased pre-surgical CD34+/CD144+ cell number in patients undergoing coronary artery bypass grafting compared to coronary artery disease-free valvular patients

  CABG Valvular P
Number 51 49 -
Age 64.65 ± 13.34 72.7 ± 10.4 0.106
Sex (Women, %) 8 (15.69%) 22 (44.89%) 0.001*
BMI (kg/m2) 26.91 ± 0.43 26.51 ± 0.57 0.5726§
EF (%) 62.51 ± 1.84 69.2 ± 1.41 0.006§
Tobacco 12 (23.53%) 9 (18.37%) 0.698*
Alcohol intake 15 (29.41%) 14 (28.57%) 0.898*
Hypertension 31 (60.78%) 27 (55.10%) 0.486*
Dyslipidemia 31 (60.78%) 16 (32.65%) 0.003*
Diabetes 24 (47.06%) 5 (10.20%) < 0.001*
ACEI/ARB 25 (49.02%) 19 (38.77%) 0.302*
Beta blockers 16 (31.37%) 9 (18.37%) 0.133*
Calcium blockers 8 (15.69%) 10 (20.41%) 0.539*
Antiplatelet drugs 33 (64.71%) 8 (16.33%) < 0.001*
Statins 34 (66.67%) 11 (22.45%) < 0.001*
Nitrates 16 (31.37%) 2 (4.08%) < 0.001*
Oral antidiabetics 16 (31.37%) 2 (4.08%) < 0.001*
Insulin 13 (25.49%) 1 (2.04%) < 0.001*
MI < 30 days 16 (31.37%) 0 (0%) < 0.001*
EuroSCORE 3.6 ± 0.4194 5.7 ± 0.4 < 0.001*
  1. * = Chi-squared test, § = Student's t test, = U Mann-Whiney-Wilcoxon test
  2. BMI: body mass index; EF: ejection fraction; MI; myocardial infarction